Search results for: Multi-Indication Medicines
Filter search results
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…The economic reality of NHS reform. What does a shift to prevention mean for the NHS? Shifting from treatment to prevention is a complex and multifaceted challenge for the NHS….
OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value
22 October 2014
…Martin Garau and Nancy Devlin [all OHE] Based on 29 pairs of medicines or indications, this poster presents research that explored the extent of NICE’s impact. Information was collected from…
An eye on sustainability at the Economist’s Future of Health Europe
30 October 2023
…tracks was ‘sustainability’. Many aspects of sustainability and what it means in a healthcare context were covered. A number of key themes emerged and were echoed by multiple participants across…
Establishing a Reasonable Price for an Orphan Drug
11 September 2020
…the parties concerned. Further research is required to improve the estimates and assumptions of key parameters (other relative operational costs, treatment populations sizes including multiple indications, average health gains, relative…
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
…the economics of the market for medicines in the UK. OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of…
Future UK Medicines Spending: Four Nation Analysis
31 October 2012
In July, OHE released projections for medicines spending in the UK NHS for 2012‒2015. We have now completed further projections, also for the ABPI, for each of the four UK…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz summarised changes implemented or…
The Economics of the Market for Medicines: 2013 Review
26 March 2013
…market for medicines in the UK. His presentation covers the key issues, from drug development through health technology assessment and market access. Economics of the Market for Medicines in the…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that will allow targeted, precision…